During the course of the past decade, three distinct developments have resulted in the widespread clinical application of intravenous anaesthesia: (a) the world-wide introduction of propofol and alfentanil in the late 1980s; (b) enhanced understanding of the pharmacodynamics and pharmacokinetics of iv anaesthetic drugs (e.g., context-sensitive half-times); (c) commercial availability of programmable ,syringe infusion pumps for intravenous infusion techniques While many of the advantages and some of the limitations of iv anaesthesia are now well-apparent, further refinement and establishment of techniques employing predominantly iv anaesthetic drugs are focusing upon several important areas. These include continued development of new, short-acting drugs which have minimal side-effects and increasingly predictable durations of action; quantitation of drug interactions; research in the area of drug delivery systems; and pharmacoeconomic evaluation of iv anaesthetic techniques. While the last two issues constitute entities unto themselves, this Refresher Course Lecture will focus primarily on new iv drugs, new methods to predict recovery from iv anaesthesia, drug interactions, and practical applications of these principles.
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During the course of the past decade, three distinct developments have resulted in the widespread clinical application of intravenous anaesthesia: (a) the world-wide introduction of propofol and alfentanil in the late 1980s; (b) enhanced understanding of the pharmacodynamics and pharmacokinetics of iv anaesthetic drugs (e.g., context-sensitive half-times); (c) commercial availability of programmable ,syringe infusion pumps for intravenous infusion techniques While many of the advantages and some of the limitations of iv anaesthesia are now well-apparent, further refinement and establishment of techniques employing predominantly iv anaesthetic drugs are focusing upon several important areas. These include continued development of new, short-acting drugs which have minimal side-effects and increasingly predictable durations of action; quantitation of drug interactions; research in the area of drug delivery systems; and pharmacoeconomic evaluation of iv anaesthetic techniques. While the last two issues constitute entities unto themselves, this Refresher Course Lecture will focus primarily on new iv drugs, new methods to predict recovery from iv anaesthesia, drug interactions, and practical applications of these principles.
Objectives
(i) To review how the characteristics of an "ideal" iv anaesthetic drug apply to the new opioid analgesic, remifentanil. (ii) To predict the potential clinical applications of an ultra-short acting opioid analgesic. (iii) To compare and contrast three predictors of recovery from iv anaesthetics: relevant effect-site decrement time, context-sensitive half-time, and mean effect time. (iv) To review basic principles of drug interaction, and to apply these to benzodiazepine/propofol, and propofol/opioid combinations. (v) To establish optimal infusion regimens for iv anaesthetic drugs. (vi) To review practical applications and techniques for obtaining maximum benefit from iv infusion anaesthesia.
New drugs
Propofol has been available in Canada for more than five years, and while many of its desirable attributes and limitations are now well-defined, t studies related to pharmacological interactions, and cost-effectiveness of this drug are ongoing. However, propofol, which has provided a major advance in clinical anaesthesia, can no longer be considered "new," and the search continues for even better sedative-hypnotics and opioid analgesics. The characteristics desirable of an "ideal" iv anaesthetic drug are listed in Table I . While many of these characteristics may appear obvious, they highlight the necessary attributes for drug development in the cost-conscious 1990s.
For new drugs to be incorporated into clinical practice, they must have unique pharmacokinetic and pharmacodynamic properties, a high therapeutic index and favourable side effect profile, while at the same time providing either a comparable, or improved cost-benefit compared with existing drugs of the same class. 2.3 In the area of sedative-hypnotics, eltanolone is being evaluated in Europe, although it appears that this drug lacks sufficient attributes to make it a replacement for propofol. Amongst the benzodiazepines, early development trials are now underway with new short-acting compounds, which appear to have many of the amnesic, anxiolytic and hypnotic advantages of midazolam, but substantially shorter recovery times. Of new opioids which are being investigated, it is the esterasemetabolised opioid analgesics (EMOAs) which appear to offer certain potential advantages over the established fentanyl/sufentanil/alfentanil family of narcotics. At the present time, particular attention is being focused upon remifentanil, due to the drug's predictability and extremely rapid recovery profile.
with a potency similar to that of fentanyl. As is the case for fentanyl, sufentanil, and alfentanil, remifentanil exerts relatively little binding at either the "~", "~" or "~i" receptor subtypes. Accordingly, the desirable clinical effects of this compound, including analgesia, sedation, MAC reduction, synergy with iv hypnotics, and haemodynamic stability, should be highly predictable. Of equal importance, the drug's side effects, including, nausea, muscle rigidity, pruritis, and respiratory depression, should be similar to the side effect profile of the other synthetic opioid "la" agonists.
The interest in remifentanil is related to one important property -its extremely short and relatively predictable duration of clinical action resulting from its distinct metabolic handling. In the circulation, remifentanil is rapidly hydrolysed by plasma and tissue esterases (tu213 = 12-25 min), producing several inactive metabolites. 4 Of equal importance from a kinetic perspective, the drug has a small volume of distribution. It is the combination of these two properties which characterizes remifentanil as a truly ultra-short acting opioid analgesic, and offers the potential for re-exploring the manner in which opioid actions are titrated to clinical effect in the perioperafive setting.
With regard to its onset of action, remifentanil achieves peak effect within the effect site (central nervous system -biophase), approximately 1-2 min following bolus injection. The drug's extremely rapid onset is similar to that of alfentanil, and is three to four times more rapid compared with either fentanyl or sufentanil, both of which require 5-6 min until maximal response is attained. However, an important pharmacodynamic distinction between remifentanil and alfentanil is that remifentanil effects are much more transient. Six minutes after bolus injections, remifentanil concentration decrease by approximately 80%, whereas alfentanil plasma levels decrease by only 60% from peak concentration during the same brief time period.
Clinical predictors of recovery from iv anaesthetics
In order to appreciate best the recovery characteristics of remifentanil, an understanding of the relative importance of the distribution and elimination processes on drug disposition within the body is essential. In general, the disposition of iv anaesthetic drugs, which equilibrate with body tissues at varying rates, can be described by the process of compartment modelling. In this process, the concentration of drug within the central compartment (essentially, the plasma) depends on the amount of drug delivered to that compartment, its volume, and rate of removal from that compartment into other body tissues (usually representing the fast and slow compartments). Because distribution processes have such an important influence on central compartment drug concentration, (and hence, clinical response), it is now well appreciated that a drug's elimination half-life is a relatively poor predictor of recovery times, following either repeated bolus administration or continuous infusion techniques.
Several clinical predictors have recently been proposed to quantitate the relative importance of elimination and distribution processes on recovery times. These predictors include: 1 relevant effect-site decrement time, s 2 context-sensitive half time, 6,7 3 mean effect time. s
The definitions, advantages and disadvantages of each of these predictors of recovery from iv anaesthetic drugs have been reviewed, 9 and are summarized in Table II . While the distinguishing features of each model can readily explain their different sensitivities in predicting recovery from a given drug, all are sensitive to the duration of drug administration, and the important influence of distribution and elimination processes on drug concentration within the central compartment at any given time (t).
To apply one of these predictors of recovery to a specific class of drugs, the context-sensitive half-times of the opioid analgesics for infusions lasting one minute, one, three and eight hours, and at steady state, are outlined in Table III . When comparing these data, it must be appreciated that the simulations assume that a pseudo-steady state concentration has been maintained at the effect site, a situation which probably occurs infrequently in clinical practice. Several aspects of Table III are noteworthy. For infusions of less than eight hours duration, the decrease in effect site concentration of sufentanil is more rapid than that of alfentanil, despite the two-fold difference in elimination half-lives R144 of these drugs (3-4 hr for sufentanil vs 1-2 hr for alfentanil). The explanation lies in the very large "slow" distribution compartment for sufentanil, which acts as a reservoir and continues to fill even after the infusion is discontinued, contributing to the decrease in plasma (and effect site) concentrations. 1~ Infusion of fentanyl is associated with considerably longer times to recovery than either sufentanil or alfentanil, except when very low serum concentrations are maintained during the course of drug administration. Although remifentanil is described by a three-compartment pharmacokinetic model, implying some potential for cumulation, the rapid metabolism and small volume of distibution of this drug suggest that the effect-site concentration of remifentanil will decrease by 80% within 10 min of stopping a continuous infusion, regardless of its duration.
Remifentanil: clinical applications
Remifentanil's extremely rapid onset, high degree of predictability, and limited potential for cumulation and rapid recovery, offer unique potential advantages for use of this drug in the perioperative setting. However, these very same characteristics may be associated with 
Potential advantages
1 Analgesic effect can be rapidly titrated due to -rapid onset of effect -extremely rapid recovery 2 Remifentanil effect closely parallels changes in infusion rate. 3 High opioid concentrations can be used intraoperatively (e.g., for TIVA) with minimal risk of postoperative respiratory depressin.
Potential disadvantages
1 Need for infusion pumps.
2 Rapid onset may result in an increased incidence of rigidity.
3 Pain or light anaesthesia will ensue very rapidly if the infusion is interrupted for any reason during the course of surgery. 4 Pain may be experienced upon arrival in the Post Anaesthesia Care Unit (requires a smooth transition to other analgesics at the end of surgery, either opioid or non-opioid).
several disadvantages (Table IV) . The role of remifentanil, and the way we practice intravenous anaesthesia, is currently being evaluated in several Phase III clinical trials. As with any new drug, the ultimate fate of remifentanil in clinical practice awaits the outcome of these studies, as well as an appropriate pharmacoeconomic evaluation.
Quantifying interactions of iv anaesthetic drugs
Newly-proposed predictors of clinical recovery have resulted in a quantal leap in our understanding of iv anaesthetic drugs. However, as optimal conditions for general anaesthesia usually require a combination of at least two drugs, it is important to appreciate the effects of varying relative drug concentrations on intraoperative conditions (haemodyamic stability, attenuation of autonomic reflexes, amnesia), and recovery profiles. In this regard, several important iv drug interactions have recently been quantitated.
Benzodiazepine-propofol interactions
Drug interactions may be either antagonistic, additive, or synergistic in nature, the latter implying that the combined drug effect is greater than the sum of its individual components.
While it is generally difficult, if not impossible, to quantify the degree of interaction between two drugs in the clinical setting due to dynamic variability (which may account for differences in clincal response as large as 300% from one patient to another), an analytical technique called isobolographic analysis was developed to evaluate the degree of synergy which exists between various drugs. As a result, combinations of benzodiazepines, barbituates, and propofol have been evaluated, from which the concept of anaesthetic "co-induction" has evolved. Several studies have shown that midazolam, in doses from 30-60 lag.kg -~ iv, decreases induction requirements of propofol by approximately 30-50%. txa2 Importantly, when midazolam (1.5-3.0 mg iv.70 kg -l) is administered prior to induction of anaesthesia, recovery times are not prolonged, even in brief outpatient procedures. ~2 While cost-savings and efficiency in drug utilization during induction are apparent, other potential advantages of this type of drug interaction include smoother maintenance of anaesthesia with reduced overall drug requirements, and possibly a lower potential for intraoperative awareness with recall, due to the specific amnesic properties of the benzodiazepine? 3 From a practical viewpoint, it is important to emphasize that co-induction is most effective when midazolam is given at least three to four minutes before the induction sequence, as the drug requires at least this amount of time to reach peak effect within the central nervous system biophase.
Propofol/opioid interactions
With regard to opioid/sedative-hypnotic drug interactions, a fundamental technique for evaluating depth of anaesthesia was provided in the seminal work of Ausems et al. in 1983.14 In studying a continuous infusion of alfentanil in combination with nitrous oxide, response/no-respone curves to various stimuli were generated, from which the plasma concentrations of alfentanil necessary to attenuate haemodynamic responses to various intraoperative noxious stimuli were determined. These findings are analagous to the concept of MAC for the inhalational anaesthetic agents, and similar investigations are being conducted with other iv anaesthetics. One of the next major advances was the development of computer-driven infusion pumps, incorporating population-pharmacokinetic data in order to achieve rapidly and maintain stable drug plasma concentrations, as developed by Schwilden et al. 15 This technique has now emerged as the state-of-the-art approach in quantitating concentration-response relations. The next logical development was to combine these two techniques, and in the mid-1990s, an important study evaluating the pharmacodynamic interaction of propofol and alfentanil was conducted. Vuyk et al. used computer-controlled infusions of propofol and alfentanil to determine propofol-alfentanil interactions for suppression of haemodynamic responses to perioperative stimuli during lower abdominal surgery. 16 It was found that by increasing the plasma concentration of alfentanil from 50 to 150 ng.ml -I, the effective concentration (ECs0) of propofol for regaining of consciousness was markedly decreased, in a non-linear manner, from 3.8 to 0.8 lag" m1-1. The non-linearity in their interaction model implies that the decrease of alfentanil requirements is R146 Initial bolus doses and infusion rates of propofol and alfentanil required to maintain a 50% probability of response to intra-abdominal surgery, while achieving the most rapid emergence from anaesthesia designed to last three hours. not proportional to incremental increases in propofol concentration, due to the synergistic interaction of propofol and alfentanil. Through the use of computer simulation models, Stanski and Shafer elegantly demonstrated how this type of information can be used clinically? 7 For example, for an anaesthetic of approximately 180 min duration, the most rapid emergence will occur if the the propofol and alfentanil concentrations are maintained at 3.5 lag. m1-1, and 85 lag-ml -J, respectively. The loading doses and infusion rates of each of these drugs necessary tO maintain these specific target concentrations are oulined in Table V . While this provides only one specific example of measuring drug interaction, this type of modelling procedure can be readily applied to other combinations of iv anaesthetic drugs as well.
In practice, of course, most clinicians employ manual infusion schemes rather than computer-assisted delivey systems. To help us in the clinical setting, computer modelling procedures can easily be extended to provide a continuum of data for the design of bolus and infusion regimens of different drugs for varying durations of adminstration, which will consistently achieve the most rapid recovery. Furthermore, these concentrationresponse data will be invaluable when computer-assisted continuous infusion (CACI) devices become commercially available, as is predicted to happen during the couse of the next several years. In reality, the value of pharmacokinetically-driven infusion devices lies in their ability to achieve and maintain a given depth of anaesthesia with intravenous medications more rapidly and easily than can be achieved using a manual infusion scheme. This is analogous to the simplicity of turning up or down the vaporizer dial with the inhalational anaesthetic drugs, according to the desired end-tidal gas concentration. Dose ranges for the opioid analgesics and sedative-hypnotics which are most suitable for administration by continuous infusion. MAC = dose ranges for monitored anaesthesia care (MAC) sedation, BAL = dose ranges for balanced anaesthesia; TIVA = dosage ranges for total intravenous anaesthesia. *Predicted requirements from initial clincial trials, requires further validation. tlag. kg -I. hr -1 (for sufentanil only).
Practical aspects of intravenous infusion techniques
Current recommendations for manual infusion schemes of iv anaesthetic drugs are listed in Table VI . The most drug required for the entire procedure, so that additional drug can be added, rather than discarded, towards the end of the operation, to minimize drug wastage. Never re-use syringes from one patient to another, especially with propofol, as this contravenes infection control guidelines! 3 Infuse drugs through a T-piece connected to the iv catheter to minimize dead space. 4 Check repeatedly for adequate flow of carrier fluid, as TIVA can become "NIVA" (no intravenous anaesthesia), with the patient awake in minutes following interruption of drug flow, for any reason. 5 During co-induction, administer midazolam at least 3-4 rain before the primary induction drug, in order to provide an appropriate onset time. 6 Hypotension during induction can be minimized by giving loading doses of opioid and propofol slowly. 7 Begin with high initial rates of infusion, then decrease rates slowly as the case proceeds, to avoid overdose. If propofol is being infused for TIVA, do not decrease the rate below 120 ~g. kg -t. min -~ until near the end of surgery. 8 Signs of light anaesthesia can be treated using supplemental boluses of propofol, midazolam and/or opioid analgesic, with or without increasing the rate of infusion. It should be remembered that rapid emergence is facilitated when relatively high opioid concentrations are achieved at the beginning of the procedure, then gradually allowed to decline during maintenance of anaesthesia. 9 Movement is a good sign of light anaesthesia, so avoid complete paralysis. The easiest way to do this for a long procedure, while maintaining adequate surgical relaxation, is to infuse the neuromuscular blocking drug. l0 A reasonable time sequence for terminating a properly titrated infusions is -opioid: 15-20 min prior to the end of surgery (except remifentanil); propofol: 5-10 min prior to the end of surgery; muscle relaxant: 10-15 min prior to the end of surgery (except mivacurium). Once the propofol is discontinued, be prepared to give small boluses of this drug (10-30 mg iv prn) if the patient becomes "light". I 1 When supplementing iv infusion anaesthesia with longer-acting inhalational agents (isoflurane or enflurane), ensure that the anaesthetic gases are discontinued well before the end of surgery (by at least 20 min), in order to achieve prompt emergence. 12 Reduce infusion rates by 25-50% for elderly patients, or those who been heavily premedicated.
Adapted from: Miller DR. Can J Anaesth 1994; 41 : 639-52.
effective manner to achieve therapeutic drug concentration rapidly is to administer a loading dose, followed by a continuous infusion, adjusted to both individual patient requirements and the varying levels of stimulation throughout surgery. Exept for drugs with the most evanescent of effects (propofol, remifentanil), infusion rates should generally be decreased over time to prevent drug accumulation. It is also important to recognize that a continuous infusion does not preclude the use of bolus doses. Boluses may be administered throughout the anaesthetic, with or without altering the rate of infusion, in order to augment drug concentration in response to actual or anticipated increases in the level of surgical stimulation. Drug bolusing will have the least impact on recovery times when using drugs which have a brief duration of action. Practical aspects of iv infusion techniques are outlined in Table VII) s Finally, it is recommended that infusion techniques be conducted using dedicated infusion pumps, in order to ensure the accuracy of infusion rates, to provide safety features, and avoid cumbersome calculations in the operating room. A number of second and third-generation devices are currently available in Canada. As has already been discussed, computer-assisted delivery devices will soon be commercially available, and may further simplify and improve the administration of iv anaesthetics by continuous infusion.
Conclusions
The availability of short-acting, potent iv anaesthetic drugs, and improvements 'in drug delivery systems specifically designed for intraoperative use, are rapidly changing the practice of anaesthesia. In concert with our improved understanding of kinetic/dynamic relationships and drug interactions, anaesthetists are being provided with the tools necessary to rapidly and precisely control independent components of the anaesthetic state (amnesia, analgesia, and muscle relaxation) in a manner never before possible. Further research, more clinical experience, and cost-benefit analyses will help forge the template to determine the ultimate role of these new drugs and techniques in the clinical practice of anaesthesia. 
L' anesth6sie intraveineuse: nouveaux agents, nouveaux concepts
Au cours de la derni~re d6cennie, trois d6veloppements remarquables sont venus 61argir le champ d'action de l'anesth6sie intraveineuse: a) l'introduction h l'6chelle mondiale du propofol et de l'alfentanil ~ la fin des ann6es 1989; b) la compr6hension de la pharmacodynamique et de la pharmacocin6tique des agents iv (par ex., la demi-vie pertinente au contexte); c) la commercialisation de pousse-seringue programmables adapt6s aux techniques de perfusion iv. Plusieurs des avantages et limites de l'anesth6sie iv sont maintenant bien connus. Le perfectionnement et la mise au point de techniques utilisant principalement des agents anestMsiques intraveineux attirent maintenant notre attention vers plusieurs innovations. Parmi celles-ci, il faut mentionner le d6veloppement ininterrompu de nouveaux agents h courte dur6e d'action ayant un minimum d'effets secondaires et des dur6es d'action de plus en plus pr6visibles; l'identification des interactions entre les agents; la recherche et le d6veloppement de syst~mes d'administration et l'6valuation pharmacologique des techniques anesth6siques iv. Bien que les deux derniers points constituent en eux-m~mes des entit~s completes, cette conf6rence d'actualisation s'adressera surtout aux nouveaux agents, aux nouvelles m6thodes de pr6diction du r6veil apr~s une anesth6sie iv, aux interactions et aux principales applications de ces principes.
Objectifs i) Comparer les caract6ristiques de l'anesth6sique id6al avec celles du nouvel analg6sique morphinique r6mifentanil. ii) Pr~dire l'application 6ventuelle en clinique d'un analg6sique morphinique ultracourt. iii) Comparer trois pr6dicteurs de la r6cup6ration apr~s un anesth6sique iv : le temps de d6croissance pertinent au site d'action, la demi-vie pertinente au contexte, et la dur6e moyenne de l'effet. iv) R~viser les principes de base de l'interaction m~dicamenteuse et les appliquer aux associations benzodiaz6pine-propofol et propofol-morphinique.
v) Etablir un sch6ma de perfusion id6al pour les anesth6siques iv. vi) R6viser les applications pratiques et techniques afin d'obtenir le b6n6fice maximal de la perfusion d'anesth6sique iv.
Nouveaux agents
Au Canada, le propofol est disponible depuis plus de cinq ans, et bien que plusieurs de ses caract6ristiques attrayantes et ses limitations soient bien d6finies, I des 6tudes sur l'interaction pharmacologique et le rapport co0t/efficacit6 se poursuivent. Cependant, le propofol, dont l'introduction en clinique repr6sente un progr~s consid6rable, n'est plus consid6r6 comme nouveau, et on est toujours h la recherche de meilleurs s6datifs/hypnotiques et de meilleurs analg6siques morphiniques. Les caract6ristiques d6sirables de !'anesth6sique iv ~ id6al >> sont 6num6r6es dans le Tableau I. Alors que plusieurs de ces caract6ristiques peuvent paraTtre 6videntes, elles soulignent les propri6t6s essentielles au d6veloppement de nouveaux produits au cours des ann6es 1990 o3 les cofit retiennent plus l'attention. Pour introduire de nouveaux produits pharmaceutiques en clinique, il faut qu'ils aient des propri6t6s pharmacocin6tiques et pharmacodynamiques uniques, un indice th6rapeutique 61ev6 et un profil d'effets secondalres favorable tout en ayant un rapport cofit/b6n6fice comparable sinon sup6rieur celui des autres produits de la m~me classe en usage. 2.3 Dans le domaine des s6datifs-hypnotiques, l'eltanolone est pr6sentement sous 6valuation en Europe, bien qu'il semble que l'eltanolone n'ait pas les qualit6s voulues pour remplacer le propofol. Parmi les benzodiaz6pines, des essais sont en cours sur au moins un produit ~ dur6e d'action ultracourte, qui semble avoir les bienfaits amn~siques, anxiolytiques et hypnotiques du midazolam, avec un temps de r~cup~ration des fonctions vitales beaucoup plus court. Parmi les nouveaux morphinique h l'6tude, ce sont les morphiniques ~ m&a-bolisme est6rasique (EMOA) qui semblent poss~der certains avantages sur la famille bien 6tablie du fentanyl/sufentanil/alfentanil. Pr6sentement, l'attention se porte sur le r6mifentanil parce que ses effets sont pr~vi-TABLEAU I Anesth6siques intraveineux: caract6ristiques d6si-rabies 
Le r~mifentanil
Le r6mifentanil est un analg6sique morphinique agoniste ~ la ~ pur, avec une puissance identique ~ celle du fentanyl. Comme le fentanyl, le sufentanil et l'alfentanil, le r6mif.entanil se lie tr~s peu aux sous-types de r6cepteurs ~ ~ ~, ~ t~ ~ ou ~ ~ ~. Pour cette raison, les effets cliniques d6sirables de ce produit, dont l'analg6sie, la s6dation, la r6duction du MAC, la synergie avec les hypnotiques iv, et la stabilit6 h6modynamique devaient &re tr~s faciles h pr6voir. D'importance 6gale, le profil des effets secondaires comme la naus6e, la rigidit6 musculaire, le prurit et la d6pression respiratoire devrait 8tre semblable au profil des autres morphiniques synth6tiques agonistes de type ~ ~ ~. Le principal int~r~t du r6mifentanil est g6n6r6 par une propri6t6 importante -sa dur6e d'action extr~mement courte et relativement pr6visible r6sultant de sa disposition m6tabolique particuli~re. Dans la circulation, le r6mifentanil est rapidement hydrolys6 par les est6rases plasmatiques et tissulaires (t~2~! = 12-25 min) pour 8tre transform6 en plusieurs m6tabolites inactifs, a En ce qui concerne sa cin6tique, le r6mifentanil a un petit volume de distribution, ce qui est aussi important. Cest l'association de ces deux propri6t6s qui caract6rise le r6mifen-tanil comme analg6sique morphinique ~ dur6e d'action ultracourte. Ces propri6t6s ouvrent une nouvelle fenStre sur la fa~on de titrer Faction des morphiniques pour utilisation clinique dans le contexte de la salle d'op6ration.
En ce qui conceme le d6but d'action, le r6mifentanil atteint son effet maximal au niveau de son site d'action (le syst~me nerveux central -biophase) environ 1 ~ 2 min apr~s son injection en bolus. Son d6but exlxSmement rapide est identique h celui de l'alfentanil, ce qui est de trois h quatre fois plus rapide que le d6but d'action du fentanyl et du sufentanil, dont la r6ponse maximale n'est atteinte quen 5-6 min. Cependant il existe une diff6rence pharmacologique importante entre le r6mifentanil et l'alfentanil; les effets du r6mifentanil sont beaucoup plus 6ph6m~res. Six minutes apr~s une injection en bolus, la concentration de r6mifentanil a diminu6 d'environ 80%, alors que la concentration plasmatique du sufentanil ne diminue qu'h 60% de la concentration maximale pendant la m~me p6riode de temps.
Facteurs cliniques prddicteurs de la rdcupdration apr~s les anesth~siques intraveineux
Pour mieux appr6cier les caract6ristiques de la r6cup6ra-tion des foncfions vitales apr~s le r6mifentanil, il est essentiel de comprendre l'importance relative des processus de distribution et d'61imination sur la disposition des drogues dans l'organisme. En g6n6ral, la disposition des anesth6siques iv, qui S'&luilibrent avec les tissus de l'organisme h des vitesses vari6es, peut ~tre d6crite comme le processus du modelage compartimental. Dans ce processus, la concentration d'une drogue l'int6rieur du compartiment central (essentiellement, le plasma) d6pend de la quantit6 de la drogue apport6e h ce compartiment, son volume et la vitesse de retrait du compartiment vers d'autres tissus (repr6sentant traditionnellement les compartiments ~ rapide ~ et ~ lent ~0. Comme la distribution a une influence tr~s importante sur la concentration de la drogue dans un compartiment (et, par cons6quent, la r6ponse clinique), on comprend mieux maintenant pourquoi la demi-vie d'61imination est un pr6dicteur relativement inefficace de la dur6e de r6cup6ration des fonctions vitales que ce soit ~ la suite d'une injection en bolus ou en perfusion continue.
Plusieurs pr6dicteurs cliniques ont 6t6 r6cemment propos6s pour quantifier l'importance relative des processus d'61imination et de distribution sur la rapid.it6 du r6veil. 1 le temps de la d6croissance au site d'action pertinent, 5 2 le demi-temps pertinent au contexte, 6,7 3 la dur6e moyenne de l'effet. Le temps n~cessaire pour que la concentration Le temps requis pour une baisse de 50% de anesthEsique au site d'action baisse h ceile du la concentration plasmatique, en fonction rEveil en rapport avecla durEe de la perfusion de la dur~e de la perfusion ('le contexte')
En rapport avec la durde d' administration

Oui Oui
Hypoth~se de modelage
Non Oui
Validation clinique
A vanta g es
Evalue la quantit6 an cerveau -le module einE-Tr~s utile pour comparer la cinEtique de deux tique le plus pertinent. Plus de dependance sur agents. La dEcroissance par palier de 50% l'hypoth~se de modelage peut 8tre plus grande que la pertinence en clinique ~t la fin de la chirurgie. En outre, les anesthEsiques iv exereent leurs effets au eerveau non darts le plasma La surface sous la courbe exprimant la probabilit6 de l'effet en fonction du moment de l'arr~t de I'administration de l'agent Oui Oui Non Incorpore ~ la fois la cinEtique et la dynamique pour pr~dire la dui~e de reffet. ImprEcis pour quantifier l'effet d'un agent (variables binaires, rEponse/absence de r~ponse)
TABLEAU 111 Demi-vie pertinente au contexte des analgEsiques morphiniques Pour appliquer un de ces prEdicteurs it une classe spEcifique d'agents, la << demi-vie pertinente au contexte, des perfusions de morphiniques d'une durEe de une minute, une, trois et huit heures, en 6tat de stabilitE, sont esquissEes au Tableau HI. Quand on compare ces donnEes, il faut reconnaitre que la simulation assume que, pour la concentration, le suppose << 6tat de stabilit6, a 6t6 maintenu au site d'action, une situation qui se prEsente relativement peu frEquemment en clinique. Plusieurs aspects du Tableau HI sont dignes de mention. Pour les perfusions qui durent moins de huit heures, la diminution de la concentration du sufentanil au site d'action est plus rapide que celle de l'alfentanil, malgr6 le fait que la difference de demi-vie d'61imination entre ces agent soit double (3-4 h pour le sufentanil vs 1-2 h pour l'alfentanil). L'explication est que le compartiment ~ lent -est trEs grand pour le sufentanil, qui agit comme un reservoir et continue de se remplir mSme apr~s l'arr~t de la perfusion, contribuant ainsi ~ la baisse de la concentration dans le plasma (et au site d'action), t~ La perfusion de fentanyl est associEe ~ des durEes de rEveil considErablement plus longues que le sufentanil ou l'alfentanil, except6 si on maintient des concentrations plasmatiques tr~s basses au cours de son administration. Bien que le rEmifentanil soit dEcrit comme un module pharmacocinEtique ~ trois compartiments, ce qui TABLEAU IV REmifentanil: avantages et dEsavantages
A vantages possibles
1 L'effet analgEsique peut ~tre titr6 rapidement ~t cause -Du debut d'action rapide -Du r6veil extrSmement rapide 2 L'effet du rEmifentanil suit de pi~s les changements de la vitesse de perfusion 3 Des concentrations peropEratoires ~levEes peuvent ~tre administr~es h peu pros sans risque de depression respiratoire
Dgsavanmges possibles
1 Le besoin d'une pompe ~t perfusion 2 Le d~but d'action rapide peut augmenter I'incidence de rigidit6 3 La douleur ou un allEgement de l'anesthEsie surviendra tr~s rapidement apr~s l'arrSt de la peffusion en cours de chirurgie 4 La douleur sera ressentie ~ l'admission ~t la salle de rEveil (nEcessit6 d'une transition en douceur avec d'autres analgEsiques morphinique ou non ~ la fin de la ehirurgie).
implique un certain potentiel d'accumulation, son mEtabolisme rapide et son petit volume de distribution sugg~re que la concentration au site d'effet diminuera par 80% dans les 10 min qui suivent l'arrEt de la perfusion, indEpendamment de sa durEe. 7 Commencer avec des vitesses de perfusion rapides, diminuer graduellement .~ mesure que la chirurgie progresse pour Eviter la surdose. Si le propofol est utilisE en AIVT, ne pas diminuer sous 120 pg. kg -I avant la fin de la chirurgie. 8 Les signes d'anesthEsie IEg~re peuvent ~tre traitEs avec des bolus de propofoi, midazolam et/ou de morphinique, sans ou avec augmentation de la vitesse de perfusion. Se rappeler qu'un r~veil rapide possible quand des concentration de morphinique relativement Elev~es sont atteintes au debut de I'intervention, puis graduellement diminu~es pendant l'entretien. 9 Comme le mouvement est un signe d'anesthEsie IEg~re, Eviter la curaristion complete. Pendant une intervention de Iongue durEe, le moyen le plus facile de 1'Eviter, est de perfuser le relaxant. I0 La chronologic suivante pour terminer une perfusion est proposEe arr~t: du morphinique 15-20 min avant la fin de la chirurgie (exceptE le rEmifentanil); du propofol 5-10 min avant la fin de la chirurgie; du relaxant musculaire, 10-15 min avant la fin de la chirurgie (exceptE le mivacurium). Une fois le propofol discontinuE, ~tre pr~t b. administrer de petits bolus de propofol (10-30 mg iv prn) si le patient s'Eveille. 11 La supplementation avec des agents d'inhalation (isoflurane ou enflurane) nEcessite que ces gaz soient discontinues bien avant la fin de la chirurgie (au moins 20 rain) pour un rEveil rapide. 12 REduire la vitesse de perfusion de 25-50% chez les gens ~gEs ou ceux qui ont EtE Iourdement pr~mEdiquEs. 
S~datifs/hypnotiques
Aspects pratiques des techniques de perfusion intraveineuse
Les recommandations actuelles pour les perfusions avec des appareils ~t rEglage manuel sont 6numErEes au Tableau VI. La faqon la plus sfire pour atteindre une concentration efficace rapidement consiste ~t administrer une dose de charge suivie dune perfusion continue, adaptEe ~ la fois aux besoins individuels du patient et aux niveaux variables de la stimulation chirurgicale. Except6 pour les agents dont les effets sont tr~s 6vanes-CANADIAN JOURNAL OF ANAESTHESIA cents (propofol, r~mifentanil), la vitesse de la perfusion devrait en gEnEral ~tre progressivement diminuEe pour prEvenir l'accumulation. II faut aussi reconna~tre quune perfusion continue n'61imine pas de faqon absolue ies doses en bolus. Les bolus peuvent ~,tre administrEs via I'anesthEsique, avec alteration ou sans alteration de la vitesse de perfusion de faqon ~ augmenter la concentration en rEponse h l'augmentation du niveau de stimulation actuei ou anticipE. Les bolus auront moins d'impact sur la durEe du rEveil si on utilise des agents dont la durEe d'action est courte. Les aspects pratiques des techniques de perfusion iv sont rEsumEs au Tableau VII. t8 Finalement, il est recommand6 que des pompes consacrEes uniquement ~ la perfusion, qui assurent la prEcision de la vitesse de perfusion, poss~dent des dispositifs de sEcurit6 et 6vitent les caiculs fastidieux en salle d'opEration. Un certain nombre d'appareils de deuxi~me et de troisi~me gEnEration sont prEsentement en usage au Canada. Comme il a 6t6 dEja mentionnE, les appareils de perfusion assistEs par ordinateur seront bient6t commercialisEs, ce qui pourrait simplifier et amEliorer I'administration des anesthEsiques iv en perfusion continue.
Conclusions
L'arrivEe d'agents anesthEsiques iv puissants et ~ courte durEe d'action, et les ameliorations apportEes aux syst~mes d'administration spEcifiquement destines ~t la salle d'opEration, font rapidement 6voluer la pratique de I'anesthEsie. En harmonie avec les progr~s de nos connaissances sur la relation cinEtique/dynamique et les interactions pharmacologiques, les anesthdsistes re~oivent les outils n6cessaires pour contrEler avec precision les composantes de l'Etat d'anesthEsie (amnEsie, anaigEsie et relaxation musculaire) d'une faqon qu'on aurait jamais crue possible. Une recherche plus poussEe, une plus grande experience clinique et des analyses de cofit par rapport au bEnEfice permettront de determiner le r61e ultime de ces nouveaux agents et de ces nouvelles techniques en anesthEsie clinique.
